Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTP 273

Next Previous
Drug Profile

TTP 273

Alternative Names: TTP-273

Latest Information Update: 28 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator vTv Therapeutics
  • Developer vTv Therapeutics LLC
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • No development reported Diabetes mellitus

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Diabetes-mellitus(Cystic fibrosis-related) in USA (PO)
  • 18 Dec 2023 vTv Therapeutics plans to terminates its licence for TTP 273 in China, Hong Kong, Macau, Taiwan, Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei, South Korea and Australia in the first half of 2024
  • 21 May 2021 Phase-I clinical trials in Diabetes mellitus (Cystic fibrosis-related) in USA (PO) before May 2021 (vTv Therapeutics pipeline, May 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top